Biotechnology

Tianlong Participated in International Medical Congress of SCO Countries in Kyrgyzstan

BISHKEK, Kyrgyzstan, April 3, 2024 /PRNewswire/ -- The International Medical Congress of the SCO countries was held on 27-29 March inBishkek, Kyrgyzstan, under the theme "Innovations and technologies in the development of cardiology and non-communicable diseases in the countries of the Shanghai C...

2024-04-03 16:16 2066

Nagase Viita Receives Highest "Platinum" Rating for Sustainability from EcoVadis

OKAYAMA, Japan, April 3, 2024 /PRNewswire/ -- Nagase Viita Co., Ltd., a NAGASE Group member headquartered in Okayama,Japan, has received the highest "Platinum" rating in a sustainability survey conducted by EcoVadis SAS ofFrance , one of the world's most trusted providers of business sustainabilit...

2024-04-03 14:00 1172

Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma™ 2024

SINGAPORE, April 3, 2024 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture announcedSingapore's top 10 Best Workplaces in Healthcare and Biopharma™  in 2024.

2024-04-03 12:00 1993

RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome

YANTAI, China, April 3, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, obtained Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) recently for its inno...

2024-04-03 11:14 1514

I-Mab Announces Closing of the Divestiture of Business Operations in China

ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all condition...

2024-04-03 04:01 1217

GC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

YONGIN, South Korea, April 2, 2024 /PRNewswire/ -- GC Cell , a fully integrated cell therapy pioneer has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data f...

2024-04-02 23:00 1718

First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH

SHANGHAI, April 2, 2024 /PRNewswire/ -- YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company'sin vivo genome editing candidate being developed as a single dose, potentially curative therapy for Familial Hypercholesterolemia(FH), marking the commencement ...

2024-04-02 20:00 1079

Origin Agritech Provides First Half Revenue Forecast and Updates Advancements in Hybrids and GMO Development

Estimated Revenue Growth of 30-40% in the First Half of FY 2024 Two New Hybrids Completed National Trials and Four GMO Corn Hybrids Currently in National Trials BEIJING, April 2, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural ...

2024-04-02 19:30 2825

CONCEPT MEDICAL RECEIVES US FDA IDE APPROVAL FOR MAGICTOUCH AVF INDICATION, THEIR FIFTH US CLINICAL STUDY APPROVAL FOR THE MAGICTOUCH PORTFOLIO

TAMPA, Fla., April 2, 2024 /PRNewswire/ -- Concept Medical has been granted 'IDE Approval' from the U.S. Food and Drug Administration (FDA) for MagicTouch AVF, its Sirolimus drug-coated balloon (DCB) catheter, to initiate a clinical study for the treatment of stenotic lesions of Arteriovenous Fis...

2024-04-02 17:33 2052

European Wellness Shines at AMWC 2024 in Monaco, with Prof. Dr Mike Chan and Prof. Dr Roni Moya as Faculty's Stem Cells Speakers

MONTE CARLO, Monaco, April 2, 2024 /PRNewswire/ -- The European Wellness Biomedical Group (EWBG), a global pioneer in biotechnology and bioregenerative medicine, is pleased to announce its extraordinary participation in the 22nd Aesthetic & Anti-Ageing Medicine World Congress (AMWC) 2024, which w...

2024-04-02 14:16 1602

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status

ROCKVILLE, Md. and SUZHOU, China, April 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune,...

2024-04-02 13:00 1820

Fosun International: Total Revenue for 2023 Reached RMB198.2 billion, Industrial Operation Profit Increased by 20% YoY

HONG KONG and SHANGHAI, April 2, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its annual results for the year ended31 December 2023 (the "Reporting Period"). During the R...

2024-04-02 11:31 2949

Kemwell BioPharma Drives Quality Excellence with Veeva Vault QMS

Pioneering biologics CDMO rapidly adopts Veeva Vault QMS to advance development and manufacturing operations BANGALORE, India, April 2, 2024 /PRNewswire/ -- Veeva Systems  (NYSE: VEEV) today announced that Kemwell BioPharma, India's largest biologics contract developmen...

2024-04-02 10:30 1580

Oncoclínicas&Co has revenues of R$6 billion and profit of R$313 million in 2023

Increase in the number of patients treated and gains in operational efficiency explain record results SÃO PAULO, April 2, 2024 /PRNewswire/ -- Oncoclínicas&Co (B3: ONCO3) – the largest group dedicated to cancer treatment inLatin America – reported a 35.1% growth in its gross revenue in 2023, tot...

2024-04-02 00:38 1575

ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones

TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of apaper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery. Together with a joint research group including investigators at theUniversity of Tokyo and the University of Brit...

2024-04-01 21:00 1683

Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification

- Lunit's AACR 2024 presentations to spotlight HER2 mutation insights and CNTN4's role in immunotherapy success, pioneering next-gen personalized treatment approaches, supported by the AI-powered Lunit SCOPE suite SEOUL, South Korea, April 1, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading...

2024-04-01 21:00 1512

Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development

PROVIDENCE, R.I., April 1, 2024 /PRNewswire/ -- In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk – a critical characterization step in the candidate dev...

2024-04-01 20:00 1934

Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO

~Hidemasa's appointment bolsters Aculys' position as a leader in the field of CNS inJapan and Asia~ TOKYO, April 1, 2024 /PRNewswire/ -- Aculys Pharma, Inc. ("Aculys"), a clinical-stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today ...

2024-04-01 14:30 1324

Hyosung TNC Invests $1 Billion in Future "Bio" Business

* Hyosung TNC to establish a new Bio-BDO (Butanediol) 50,000 ton factory in Vietnam with plans to expand future plants to an annual output of 200,000 tons  * Replacing fossil raw materials with those from sugarcane, entering the bio raw material market  * Applications across various industri...

2024-04-01 08:18 1435

LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC)

* Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported to be in clinical development for the treatment of PSC * FDA's Fast Track designation for LB-P8 underlines the urgent need for treatment options to fulfill the unmet medical needs of people affecte...

2024-03-29 21:00 2316
1234567 ... 278